马来酸依那普利/盐酸乐卡地平(Enalapril Maleate/Lercanidipine Hydrochloride) - 药物靶点：ACE x VDCCs_在研适应症：高血压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Atover、Carmen ACE、Coripren

+ [9]

靶点

ACE x VDCCs

作用机制

ACE抑制剂(血管紧张素转化酶抑制剂)、VDCCs阻滞剂(电压门控性钙通道复合体阻滞剂)

治疗领域

心血管疾病

在研适应症

高血压

非在研适应症-

原研机构

Recordati SpA

在研机构

Viatris Pty Ltd.

Recordati SpA

非在研机构-

最高研发阶段批准上市

首次获批日期

澳大利亚 (2008-02-14),

高血压

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C36H42ClN3O6

InChIKeyWMFYOYKPJLRMJI-UHFFFAOYSA-N

CAS号132866-11-6

查看全部结构式(2)

关联

2

项与马来酸依那普利/盐酸乐卡地平相关的临床试验

NCT01211314 / Terminated临床4期IIT

Treatment of Essential Hypertension With Vasodip-Combo 20. Efficacy and Safety Evaluation With 24 h Ambulatory Blood Pressure Measurements

Treatment and control of hypertension is still insufficient. About 50% of the patients remain uncontrolled. Lack of compliance with discontinuation of drug treatment is an important reason for not achieving blood pressure. Several studies have shown that use of fixed combinations improve compliance significantly, by reducing the number of pill's intake.
This study will assess the antihypertensive efficacy of Vasodip-Combo 20® [enalapril 20 mg + lercanidipine 10 mg] as a fixed combination drug in uncontrolled antihypertensive patients.

开始日期2011-01-01

申办/合作机构

Meir Medical Center

[+1]

NCT01093807 / Completed临床2期

Randomized, Parallel Group, Double-blind Trial to Evaluate Different Dose Combinations of Lercanidipine and Enalapril in Comparison With Each Component Administered Alone and With Placebo in Patients With Essential Hypertension

The purpose of this study is to evaluate the efficacy and safety of various dosage combinations of lercanidipine (10 and 20 mg)and enalapril (10 and 20 mg) in comparison with their respective components and with placebo.

开始日期2010-03-01

申办/合作机构-

100 项与马来酸依那普利/盐酸乐卡地平相关的临床结果

登录后查看更多信息

100 项与马来酸依那普利/盐酸乐卡地平相关的转化医学

登录后查看更多信息

100 项与马来酸依那普利/盐酸乐卡地平相关的专利（医药）

登录后查看更多信息

49

项与马来酸依那普利/盐酸乐卡地平相关的文献（医药）

2024-01-24·ACS Applied Materials & Interfaces

Heteromultivalent Ligand Display on Reversible Self-Assembled Monolayers (rSAMs): A Fluidic Platform for Tunable Influenza Virus Recognition

Article

作者: Sellergren, Börje ; Yeung, Sing Yee ; Sergeeva, Yulia

We report on the design of heteromultivalent influenza A virus (IAV) receptors based on reversible self-assembled monolayers (SAMs) featuring two distinct mobile ligands. The principal layer building blocks consist of α-(4-amidinophenoxy)alkanes decorated at the ω-position with sialic acid (SA) and the neuraminidase inhibitor Zanamivir (Zan), acting as two mobile ligands binding to the complementary receptors hemagglutinin (HA) and neuraminidase (NA) on the virus surface. From ternary amphiphile mixtures comprising these ligands, the amidines spontaneously self-assemble on top of carboxylic acid-terminated SAMs to form reversible mixed monolayers (rSAMs) that are easily tunable with respect to the ligand ratio. We show that this results in the ability to construct surfaces featuring a very strong affinity for the surface proteins and specific virus subtypes. Hence, an rSAM prepared from solutions containing 15% SA and 10% Zan showed an exceptionally high affinity and selectivity for the avian IAV H7N9 (K_d = 11 fM) that strongly exceeded the affinity for other subtypes (H3N2, H5N1, H1N1). Changing the SA/Zan ratio resulted in changes in the relative preference between the four tested subtypes, suggesting this to be a key parameter for rapid adjustments of both virus affinity and selectivity.

2024-01-01·Therapeutic Advances in Medical Oncology

Network meta-analysis of novel targeted therapies for relapsed/refractory chronic lymphocytic leukemia

Article

作者: Reczek, Monika ; Monica, Magdalena ; Kawalec, Paweł

Background: The recent development of new antileukemic therapies (anti-CD20 monoclonal antibodies, Bruton tyrosine kinase inhbitors, phosphoinositide 3-kinase inhibitors, and B-cell lymyphoma-2 antagonists) improved the progression-free survival (PFS) compared with selected standard regimens in clinical trials for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Unfortunately, the relative efficacy of all possible therapeutic options remains unknown because there is no direct evidence for all possible comparisons. Objectives: We aimed to compare the efficacy and safety of novel agents, chemotherapy, and immunotherapy using a Bayesian network meta-analysis (NMA). Design: Systematic literature review with Bayesian NMA. Methods: An extensive systematic literature review of randomized clinical trials for relapsed/refractory CLL was performed. We searched for articles indexed in medical databases (MEDLINE, Embase, The Cochrane Library) and gray literature that could be further implemented into the Bayesian NMA. Results: The systematic search identified 15 randomized trials that formed networks comparing PFS, overall survival (OS), overall response rates, and serious adverse events. Our study showed that all regimens containing novel agents significantly prolonged PFS compared with standard chemoimmunotherapy and immunotherapy. Among targeted drugs, venetoclax (VEN) + rituximab (RTX) had comparable efficacy in terms of PFS to zanubrutinib (ZAN) [hazard ratio (95% credible interval), 1.10 (0.59–2.08)], acalabrutinib (ACA) [0.78 (0.47–1.30)], ibrutinib (IBR) monotherapy [0.72 (0.41–1.27)], and other IBR-based regimens. ZAN was superior to IBR monotherapy [0.65 (0.49–0.86)] but not to ACA [0.71 (0.49–1.02)]. There were no significant differences in OS in any of the above comparisons. Conclusion: All novel therapies have better efficacy than chemoimmunotherapy and immunotherapy regimens. Among novel agents, the relative efficacy of VEN + RTX was similar to all BTKi, while ZAN was superior to IBR and comparable to ACA. Trial registration: PROSPERO CRD42022304330.

2024-01-01·Asian Pacific Journal of Allergy and Immunology

A new pepper allergen Zan b 1.01 of 2S albumins: Identification, cloning, characterization, and cross-reactivity

Article

作者: Liu, Siyu ; Zhu, Liping ; Hu, Jing ; Tang, Rui ; Zhang, Yuzhu ; Ni, Kang ; Sun, Jing-Lyu ; Ye, Xiaodong ; Jin, Tengchuan ; Ma, Li ; Li, Hong ; Chen, Feng ; Wang, Rui-Qi ; Zhu, Lixia

BACKGROUNDZanthoxylum bungeanum (Sichuan pepper; in Chinese) is used as a spice worldwide and is a potentially life-threatening allergenic food source, as first reported by our team in 2005. However, its allergen components are unknown.OBJECTIVEWe aim to identify and characterize its major allergen and determine its cross-reactivities with citrus seeds, pistachios, and cashew seeds.METHODSIonic exchange and molecular exclusion chromatography were used to isolate the protein components from Sichuan pepper seed. A protein fraction was characterized by SDS-PAGE, analytical ultracentrifugation, mass spectrometry, and circular dichroism spectroscopy. The coding region of it was amplified from the genome. ELISA and competitive ELISA assays were used to investigate the allergenicity and cross-reactivity of allergens.RESULTSThis protein allergen was around 14 kDa. It was a 2S albumin similar to an α-Amylase inhibitor (AAI) domain-containing protein of Citrus sinensis. Circular dichroism spectroscopy showed its thermal stability was high. A 303 bps DNA sequence of the AAI domain was cloned from the genome of the Sichuan pepper. Competitive ELISA assays showed positive cross-reactivities between this allergen and citrus seeds, pistachios, and cashew seeds.CONCLUSIONA major allergen of around 14 kDa from Sichuan pepper seed was confirmed, which belongs to the 2S albumin of plant seed storage proteins. Based on the nomenclature of the IUIS Subcommittee for Allergen Nomenclature, this allergen is designated as Zan b 1.01. The cross-reactivities were demonstrated between Zan b 1.01 and citrus seeds, pistachios, and cashew seeds.

100 项与马来酸依那普利/盐酸乐卡地平相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	C09BB02	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高血压	澳大利亚	Viatris Pty Ltd.	2008-02-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01093807 (Pubmed \| J Hypertens)	临床2期	高血压	1,039	Placebo	襯簾鬱遞觸簾獵襯餘願(鏇襯艱廠製簾鏇鹽襯鏇) = 繭構壓積遞襯獵選顧齋鏇鑰衊鬱選壓夢獵艱廠 (窪製襯糧鏇遞壓製衊築 ) 更多	-	2016-01-01
				Lercanidipine 10mg	襯簾鬱遞觸簾獵襯餘願(鏇襯艱廠製簾鏇鹽襯鏇) = 窪壓襯淵醖鬱餘鏇選願鏇鑰衊鬱選壓夢獵艱廠 (窪製襯糧鏇遞壓製衊築 ) 更多